glp 1 agonist bone density Frontiers GLP-1 medications can be a

Obes Surg (2008) 18(9):11837

For instance, SAR441255designed with balanced activity across all three receptorsshowed some promising early efficacy for glycaemic control in a phase 1 single-dose study and was generally well tolerated [65], however, no further trials have been reported since 2019

Glucagon-like peptide-1 (GLP-1) receptor agonists: applications in childhood diabetes and obesity

Gut microbiota composition (including Firmicutes , Bacteroidetes , Akkermansia , and Bifidobacterium ) influences host metabolism by producing short-chain fatty acids (SCFAs), generating secondary bile acids, modulating immune and inflammatory pathways, and stimulating GLP-1 secretion from intestinal L-cells

As of now, GLP-1-related triple agonists are primarily still in the development stage and have not been widely approved for use